PRAME Expression Correlates With Genomic Aberration and Malignant Diagnosis of Spitzoid Melanocytic Neoplasms
- PMID: 35503885
- PMCID: PMC11010723
- DOI: 10.1097/DAD.0000000000002208
PRAME Expression Correlates With Genomic Aberration and Malignant Diagnosis of Spitzoid Melanocytic Neoplasms
Abstract
Spitzoid melanocytic neoplasms are a diagnostically challenging class of lesions in dermatopathology. Recently, molecular assays and immunohistochemical markers have been explored as ancillary methods to assist in the diagnostic workup. Specifically, preferentially expressed antigen in melanoma (PRAME) immunohistochemistry is a nuclear stain commonly positive in melanomas, but not in nevi. This study investigates PRAME immunoreactivity (≥75% positive nuclear staining in tumor cells) in a set of 59 spitzoid melanocytic neoplasms with known clinical outcomes. We compared PRAME status with (1) the clinical outcomes, (2) the morphologic diagnoses, and (3) the status of TERT promoter mutation. Regarding clinical outcomes, 3 cases developed metastatic disease, of which 2 expressed diffusely positive PRAME staining. Of the 56 cases that did not show evidence of metastasis, 6 expressed diffusely positive PRAME staining. Morphologically, diffusely positive PRAME staining was seen in 7 of 21 cases (33.3%) diagnosed as melanoma and only 1 benign tumor 1 of 38 (2.6%). There were 4 of 8 cases with a TERT promoter mutation which were diffusely PRAME-positive compared with 4 of 51 cases without TERT promoter mutation ( P = 0.001). Our results show a statistically significant correlation between PRAME expression and the diagnosis, outcome, and TERT promoter mutation status of atypical spitzoid melanocytic neoplasms, suggesting immunohistochemistry for PRAME can help support a suspected diagnosis. However, because of occasional false-positive and negative test results, correlation with the clinical and histologic findings as well as results from other tests is needed for the interpretation of diagnostically challenging spitzoid melanocytic neoplasms.
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
Conflict of interest statement
Conflict of Interest
The authors have disclosed that they have no significant relationships with, or financial interest in, any commercial companies pertaining to this article.
Figures




Similar articles
-
PRAME immunohistochemistry of spitzoid neoplasms.J Cutan Pathol. 2022 Aug;49(8):709-716. doi: 10.1111/cup.14245. Epub 2022 May 24. J Cutan Pathol. 2022. PMID: 35488519
-
PRAME Immunohistochemical Expression and TERT Promoter Mutational Analysis as Ancillary Diagnostic Tools for Differentiating Proliferative Nodules From Melanoma Arising in Congenital Nevi.Am J Dermatopathol. 2023 Jul 1;45(7):437-447. doi: 10.1097/DAD.0000000000002357. Epub 2023 Feb 17. Am J Dermatopathol. 2023. PMID: 37338065
-
PRAME expression in melanocytic proliferations with intermediate histopathologic or spitzoid features.J Cutan Pathol. 2020 Dec;47(12):1123-1131. doi: 10.1111/cup.13818. Epub 2020 Sep 10. J Cutan Pathol. 2020. PMID: 32700786
-
PRAME Immunohistochemistry as an Ancillary Test for the Assessment of Melanocytic Lesions.Surg Pathol Clin. 2021 Jun;14(2):165-175. doi: 10.1016/j.path.2021.01.001. Epub 2021 Apr 28. Surg Pathol Clin. 2021. PMID: 34023098 Free PMC article. Review.
-
Pitfalls of PRAME Immunohistochemistry in a Large Series of Melanocytic and Nonmelanocytic Lesions With Literature Review.Am J Dermatopathol. 2024 Jan 1;46(1):21-30. doi: 10.1097/DAD.0000000000002584. Am J Dermatopathol. 2024. PMID: 37982498 Review.
Cited by
-
PRAME Is an Effective Tool for the Diagnosis of Nevus-Associated Cutaneous Melanoma.Cancers (Basel). 2024 Jan 9;16(2):278. doi: 10.3390/cancers16020278. Cancers (Basel). 2024. PMID: 38254769 Free PMC article.
-
A Physician's Guide to the Use of Gene Expression Profile Ancillary Diagnostic Testing for Cutaneous Melanocytic Neoplasms.J Clin Aesthet Dermatol. 2023 Apr;16(4):12-20. J Clin Aesthet Dermatol. 2023. PMID: 37077930 Free PMC article. Review.
-
PRAME immunohistochemistry in soft tissue tumors and mimics: a study of 350 cases highlighting its imperfect specificity but potentially useful diagnostic applications.Virchows Arch. 2023 Aug;483(2):145-156. doi: 10.1007/s00428-023-03606-6. Epub 2023 Jul 21. Virchows Arch. 2023. PMID: 37477762
-
PRAME Updated: Diagnostic, Prognostic, and Therapeutic Role in Skin Cancer.Int J Mol Sci. 2024 Jan 27;25(3):1582. doi: 10.3390/ijms25031582. Int J Mol Sci. 2024. PMID: 38338862 Free PMC article. Review.
-
Utilizing PRAME Expression and a Meta-Analytic Framework for iSALT to Explore Atypical Late-Onset Nevi of the Elderly and Their Relationship With Lentiginous and Nested Nevoid Melanomas.Am J Dermatopathol. 2024 Dec 1;46(12):825-832. doi: 10.1097/DAD.0000000000002847. Epub 2024 Oct 15. Am J Dermatopathol. 2024. PMID: 39412342 Free PMC article.
References
-
- Cerroni L, Barnhill R, Elder D, Gottlieb G, Heenan P, Kutzner H, et al. Melanocytic tumors of uncertain malignant potential: results of a tutorial held at the XXIX Symposium of the International Society of Dermatopathology in Graz, October 2008. Am J Surg Pathol. 2010. Mar;34(3):314–26. doi: 10.1097/PAS.0b013e3181cf7fa0. PMID: 20118771. - DOI - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical